ArticleNeurology. Genetics2026
Beyond Seizure Management in a Developmental Epileptic Encephalopathy: Expanding the SLC6A1 Neurodevelopmental Disorder Phenotype.
Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD) is emerging as a leading genetic cause of epilepsy, autism spectrum disorder (ASD), and NDD caused by monoallelic loss of function variants in SLC6A1 (solute carrier family 6 member 1) which encodes a gamma-aminobutyric acid (GABA) transporter (GAT1). Descriptions of SLC6A1-NDD have centered around epilepsy, but caregivers report other features that drive key aspects of the disease burden. This retrospective chart review and prospective natural history study (NHS) aims to highlight the nonseizure clinical features of SLC6A1-NDD. Methods: Medical records of individuals with SLC6A1-NDD from University of Texas Southwestern (UTSW) and from the Children's Hospital of Philadelphia (CHOP) were reviewed. Participants had a confirmed or strongly suspected pathogenic variant in SLC6A1. Twenty of these individuals were also enrolled in an NHS at UTSW which included standardized scales and caregiver interviews. Results: Sixty-three individuals were included (40 from UTSW, 23 from CHOP) with 31 males. Developmental delay was present in 97%, developmental regression in 41%, and 58% of those had an atypical regression. Of the total cohort, 60% have ASD. Maladaptive behaviors were present in a majority with aggression occurring in 57% of those. Twenty individuals completed standardized scales as part of the NHS at UTSW. The developmental coordination disorder questionnaire (DCDQ) demonstrated that 90% met criteria for probable developmental coordination disorder. Sleep problems were reported in 56%, but when assessed with the sleep disturbance scale for children (SDSC), all NHS participants scored >39, indicating clinically significant sleep problems. Total SDSC score positively correlated with behavior problems. Discussion: Daily effects from SLC6A1-NDD cannot be described by epilepsy alone. Combining retrospective and prospective NHS data expands phenotypic and genotypic knowledge. We report the highest association with ASD and unusual developmental regression patterns. Maladaptive behaviors are frequent, commonly aggression. DCDQ and SDSC scores correlated with caregiver concerns but also found higher instances of movement and sleep problems, underrecognized by caregivers and providers. Often, odd movements defy categorization between stereotypies, tics, and epileptic movements. GABA homeostasis disruptions are integral to symptom formation but require better understanding.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.